Related Experiment Videos
[Quinolones in the treatment of bacterial endocarditis]
Abstract:
The authors submit available information on the restricted use of new antimicrobial chemotherapeutic agents--quinolones--in the treatment of bacterial endocarditis in experiments and under clinical conditions. Quinolones are not suitable for the treatment of endocarditis except when the aetiological agent is Ps. aeruginosa, enterobacteria and in some instances endocarditis caused by meticillin-resistant staphylococci. The mentioned aetiological agents, however, cause endocarditis only in cca 5-10%. The results of experimental investigations on animal models as well as case-histories from human medicine are promising in this respect.
Insights
New quinolone antimicrobial agents show limited utility in treating bacterial endocarditis. They are effective only for specific pathogens like Pseudomonas aeruginosa and certain resistant bacteria, representing a small percentage of cases.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Context:
- Bacterial endocarditis is a serious infection requiring effective antimicrobial therapy.
- Newer antimicrobial agents, specifically quinolones, are being evaluated for clinical applications.
- The efficacy of quinolones in treating bacterial endocarditis remains under investigation.
Purpose:
- To assess the restricted use and efficacy of quinolone antimicrobial agents in treating bacterial endocarditis.
- To evaluate the suitability of quinolones against specific etiological agents of endocarditis based on experimental and clinical data.
Summary:
- Quinolones demonstrate limited effectiveness in treating bacterial endocarditis.
- Their use is restricted to cases caused by Pseudomonas aeruginosa, enterobacteria, and some meticillin-resistant staphylococci.
- These specific pathogens account for only about 5-10% of endocarditis cases.
Impact:
- Findings suggest quinolones are not a first-line treatment for most bacterial endocarditis cases.
- Experimental and clinical data indicate potential promise for quinolones in niche endocarditis scenarios.
- Further research may refine the role of quinolones in managing specific, difficult-to-treat endocarditis infections.